Results of pivotal trial of Cerezen™ in 190 subjects with mild cognitive impairment (MCI) or Alzheimer’s disease.
Indications for Use: Cerezen™ is indicated for the treatment of mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.
Granted Designation as a Breakthrough Device by the FDA
HOWEVER, CURRENTLY NOT CERTIFIED IN THE U.S.
Ask your U.S. Representative and the FDA why this Breakthrough Device isn’t yet approved in the United States.
*2025 statistics from the Alzheimer’s Association at alz.org